FDA approves Medtronic’s adaptive deep-brain stimulator for Parkinson’s disease
The company said its U.S. rollout represents the largest-ever commercial launch of a brain-computer interface technology, with Medtronic’s BrainSense platform reading changes in a patient’s neural activity in real-time and then adjusting therapy to suit.
The company said its U.S. rollout represents the largest-ever commercial launch of a brain-computer interface technology, with Medtronic’s BrainSense platform reading changes in a patient’s neural activity in real-time and then adjusting therapy to suit.
